CD38 and Miyoshi myopathy: In a subgroup analysis of the MAbs targeting CD38 group, the HR for the PFS of the daratumumab group vs control group was 0.40 (95%CI 0.32–0.48) as compared to 0.60 (95%CI 0.41–0.78) of the isatuximab group vs control group, suggesting that the daratumumab group may result in longer PFS than the isatuximab group in patients with relapsed or refractory MM.